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Abstract
The higher the pressure to win, the more athletes are inclined to take steps to improve 
one’s performance through questionable means. To minimize this, strict anti‐doping 
and medication rules are being enforced. All human and equine athletes are regularly 
subjected to doping analysis to prevent abuse of forbidden substances from affecting 
their performance. Anabolic‐androgenic steroids (AASs) have been part of the forbidden 
substances list for years, because of their muscle building and performance‐enhancing 
capacities and possible side effects. For most of the AAS, zero‐tolerance is held. However, 
some AASs can be endogenous to the athletes, such as for example testosterone in males. 
These endogenous steroids can render it very difficult to reveal steroid abuse. Specific 
mass spectrometric (MS) methods, including ultra‐high performance liquid chroma‐
tography‐MS (UHPLC‐MS/MS), high resolution mass spectrometry (HRMS) and gas 
chromatography–combustion‐isotope ratio MS (GC‐C‐IRMS), have been put forward 
to overcome these analytical difficulties. Currently, high‐tech metabolomic methods are 
being used to build athlete specific biological passports. In the near future, these pass‐
ports might allow putting a stop to abuse, by staying ahead of the cheats. These are bright 
prospects, leading towards clean and fair sports competitions worldwide.
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1. Introduction
1.1. Steroid structures
Steroids are cyclic, organic compounds with basic skeleton 17 carbon atoms (C17) arranged in 
a four‐ring structure: three C6 rings, followed by a C5 ring and a C8 side chain linked to C‐17. 
The four‐ring structure is formed after cyclization of a C30 chain, squalene, into lanosterol or 
cycloartenol [1]. The three cyclohexane rings are designated as rings A, B and C and the cyclo‐
pentane ring as ring D. The three cyclohexane rings form the skeleton of a perhydro‐ derivative 
of phenanthrene. The D‐ring has a cyclopentane structure; hence, though it is uncommon, 
IUPAC steroids can also be named as various hydro‐derivatives of cyclopentaphenanthrene 
(Figure 1A). This 17‐carbon compound is also called gonane, the simplest steroid and a sub‐
structure present in most steroids. When the two methyl groups (C‐10 and C‐13) and C8 side 
chain (at C‐17) are present, the steroid is said to have a cholestane framework (5α‐cholestane, 
a common steroid core, e.g. cholesterol, Figure 1B). Cholesterol is the precursor of steroids in 
both humans and animal species [2].
Despite the shared basic steroid skeleton, hundreds of different steroids can be found in 
animals, plants and even fungi. They include the sex hormones such as 17β‐estradiol and 
testosterone, bile acids, phytosterols, cortisol and drugs such as the anti‐inflammatory cor‐
ticosteroids (e.g. dexamethasone, prednisolone), ergosterols and many more. Individual ste‐
roids vary by the oxidation state of the carbon atoms in the rings (single or double bounds) 
and by the chain and functional groups attached to the four‐ring skeleton [3].
Additionally, steroids can vary more markedly via changes to the ring structure (e.g. via ring 
scissions that produce secosteroids). Secosteroids enhance intestinal absorption of calcium, iron, 
magnesium, phosphate and zinc. In humans, the most important compounds in this group are 
vitamin D3 (also known as cholecalciferol) and vitamin D2 (ergocalciferol) [4]. Sterols, includ‐
ing cholesterol and phytosterols, are another particularly important form of steroids, having 
a cholestane‐derived framework and a hydroxyl group at the C‐3 position (e.g. cholesterol, 
Figure 1B) [5]. These closely related chemical structures of the different steroids already illus‐
trate the challenges faced with steroid detection, identification and quantification methods.
Figure 1. (A) Chemical structure of the basic steroid cyclopentaphenanthrene skeleton including IUPAC‐approved 
ring lettering and (B) chemical structure of cholesterol, including all normally seen branches, atom numbering and 
stereochemistry.
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1.2. Natural steroids and their role in the endocrine system
Hormones are chemical compounds that are naturally produced by both animals and 
human beings and have a number of important functions in life, such as reproduction 
and growth. They act as signalling molecules between the different parts of the organism 
and trigger and modulate key reactions to support and promote life [6]. The most well‐
known hormones are the steroid hormones, e.g. 17β‐estradiol, progesterone and testoster‐
one, which are involved in endocrine regulation pathways. Next to influencing reproduction 
and growth, these steroids play other important roles as well. Testosterone regulates protein 
synthesis, 17β‐estradiol triggers protein disposition and progesterone has an antagonistic 
role in oestrogens.
In mammals, including horses and humans, steroid hormones are secreted primarily by the 
testicles of males and the ovaries of females, although smaller amounts are also secreted by the 
adrenal glands (Figure 2). The adrenal glands are located just in front of the kidneys and consist 
of two parts, the cortex and the medulla. The adrenal cortex consists of three layers, each of 
which produces a different set of steroid hormones. The inner layer produces sex hormones 
such as oestrogen and progesterone [6, 7].
Next to adrenal and gonadal production of steroids, recent papers implied that uterine and 
oviductal tissues can produce steroids as well [8–10]. Adipose tissue is also no longer consid‐
ered to be an inert tissue that stores fat. White adipose tissue (WAT) is now being recognized as 
a major endocrine and secretory organ, releasing a wide range of protein factors and signals 
termed adipokines, in addition to fatty acids and other lipid moieties [11, 12].
In general, steroid hormone biosynthesis involves a battery of oxidative enzymes located in 
two distinct cell organelles: mitochondria and the endoplasmic reticulum (ER). The transport 
of free cholesterol from the cytoplasm into mitochondria is the rate‐limiting step in this pro‐
cess. CYP11A1, an enzyme bound to the inner membrane of mitochondria, will initiate the 
biosynthesis by converting cholesterol into pregnenolone. Pregnenolone (3β‐hydroxypregn‐ 
5‐en‐20‐one, also known as P5) undergoes further steroid metabolism in one of three ways, 
making it the immediate precursor for the synthesis of all of the other steroid hormones, 
including progestogens, mineralocorticoids, glucocorticoids, androgens and oestrogens, as 
well as the neuroactive steroids [1].
Figure 2. Endocrine system of humans and horses. The adrenal glands and gonads (ovaries in females and testicles in 
males) are the main organs involved in steroid biosynthesis. Reproduced from https://medlineplus.gov/endocrinesystem.
html and the Merck Veterinary Manual (2010).
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Figure 3. Jockey Bob Ussery celebrating with Dancer’s Image after his fraudulent win at Kentucky Derby in 1968.
1.3. Anabolic‐androgenic steroids (AAS)
The term anabolic‐androgenic steroids (AASs) is used to group the naturally occurring male 
sex hormone testosterone, testosterone precursors and metabolites, and sometimes also (syn‐
thetically) produced testosterone variants [13, 14]. ‘Anabolic’ refers to the muscle‐building 
capacity, ‘androgenic’ refers to increased male sexual characteristics and ‘steroid’ refers to the 
class of these compounds (Section 1.1).
Valid medicinal use of AAS is limited. It is only allowed to use it in the treatment of patients 
with a negative nitrogen balance, like weakened horses, or to accelerate healing after trauma 
or surgery. Anabolic steroids can be given by injection, taken orally or used externally. In 
humans, AASs are classified as controlled substances, due to the possibility of serious adverse 
effects and a high potential for abuse, as these hormones increase lean muscle mass and can 
improve athletic performance.
Nevertheless, non‐therapeutic (abuse) of AAS has been a matter of all times. The first wide‐
spread usage of steroids and other forbidden substances in horses dates back to the early 1960s 
and 1970s (Figure 3). In humans, the first documented use of testosterone as a performance‐
enhancing substance in sport was already reported in the early 1950s. Russian weightlifters 
out‐competed all other athletes and their trainers conceded that they were using testosterone.
Anti‐doping policies in horse racing and other horse sports date back to the ‘1960s. In May 
1968, the first horse, Dancer’s Image, winner in the Kentucky Derby, was disqualified for 
using a banned substance. Traces of phenylbutazone, a non‐steroidal anti‐inflammatory drug 
(NSAID), were found in his urine post‐racing (Figure 3).
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2. Doping regulations for horses and humans
2.1. Human athletes
In response to the widespread (abuse) of steroids, the American Congress developed the 
Anabolic Steroids Control Act in 1990, placing steroids in the same legal class (class III con‐
trolled substances) as amphetamines, methamphetamines, opium and morphine. The World 
Conference on Doping in Sport held in Lausanne (1999) produced the Lausanne Declaration 
on Doping in Sport. This document provided for the creation of an independent international 
anti‐doping agency to be fully operational for the Olympic Games in Sydney (2000). Pursuant 
to these terms set by the Lausanne Declaration, the World Anti‐Doping Agency (WADA) was 
established on the 10th of November 1999 (Lausanne, Switzerland). Since then WADA aims 
to promote and co‐ordinate the fight against doping in sport internationally. WADA was 
founded under the initiative of the International Olympic Committee (IOC), and the IOC still 
occupies 50% of the positions within the agency. The other 50% of the representatives belong 
to inter‐governmental organizations and governments, public authorities and other public 
and private bodies that are also involved in the fight against doping in sport [15].
Currently, AASs are still classified as class III controlled substances (class S1 anabolic agents), 
they are part of the first section of WADA’s List of Prohibited Substances and Methods (2017), 
which discusses substances and methods that are prohibited at all times, both in‐competition 
and out‐of‐competition, and any athlete can be tested for these substances at any time. The 
list of anabolic agents is extensive and even if one is not specifically listed, it is still prohib‐
ited if it is a metabolite or has a similar chemical structure or similar biological effect(s) to 
anabolic agents (WADA, 2017 List of Prohibited Substances and Methods). The list includes 
both exogenous (S1 1.a.) and endogenous anabolic‐androgenic steroids (when administered 
exogenously) (S1 1.b.).
2.2. Race and sport horses
Race and sport horses are, just like human athletes, frequently subjected to doping controls to 
guarantee a safe and fair competition. Fédération Equestre Internationale (FEI), responsible for all 
Olympic disciplines including jumping, dressage, endurance and eventing and International 
Federation of Horseracing Authorities (IFHA) regulations state that ‘any use of substances with 
a potential to affect equine performance, health or welfare and/or with a high potential for misuse is 
contrary to the integrity of equestrian sport and the welfare of the horses’.
As strict zero‐tolerance has been held for many years, anabolic‐androgenic steroids might 
seem to be an issue of the past as new and possibly more effective ‘designer’ drugs have been 
developed over the years (e.g. AICAR, a metabolic modulator and TB‐500, a synthetic peptide 
stimulating muscle development in horses [16, 17]). However, recent cases of steroid abuse 
(FEI equine anti‐doping decisions, 2013–2016) prove that, although AAS abuse is better under 
control than it was some decades ago, it will be of all times. The potential of AAS to improve 
performance remains too tempting to some trainers and riders, and not only in racing and 
endurance. If Group VII (Middle‐East) countries were excluded from the endurance records, 
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endurance worldwide even has a cleaner AAS abuse record than show jumping. This illustrates 
that, unfortunately and despite great efforts from the regulatory bodies, AAS abuse is still 
rooted deeply into different equine sport disciplines at both the amateur and professional level.
Additionally, there is no worldwide restriction to the use of AAS as growth promoting and 
performance‐enhancing agents. Boldenone (Bol), androstadienedione (ADD) and Bol esters, 
for example, are easily available on the (European) black market as anabolic preparations, 
imported from the US [18]. In the United States, it also took until 2008 for steroids to be banned 
from the racing courses. Under this more recent law, a horse may be given steroids only 
under certain therapeutic conditions, and a horse may not race for at least 60 days afterwards 
(Press release, Kentucky Horse Racing Commission website, September 5, 2008 and Racing 
Medication and Testing Consortium (RMTC), 2008). In Australia, anabolic steroids were only 
prohibited on race day, but a new total ban (November 1st 2013 and effective from May 1st 
2014, Australian Racing Board, ARB) applies to all thoroughbreds from the age of 6 months, 
both in‐ and out‐of‐competition. These decisions have been welcomed by the IFHA and FEI, 
to further two of their key objectives, being to co‐ordinate and harmonize the rules of all 
member countries worldwide.
3. How endogenous AAS complicate anti‐doping analysis
Steroids can be classified into three broad classes: exogenous, designer and endogenous ste‐
roids. With the present‐day AAS abuse issue in mind, the development of new and better 
detection techniques is needed to detect and to distinguish between steroids belonging to 
these different classes. Additionally, not only AAS but also oestrogens, gestagens and andro‐
gens (EGAs) as well as thyreostats, corticosteroids and β‐agonist compounds, are used alone 
or in growth promoting ‘cocktails’ with low concentrations of several compounds, compro‐
mising their detection [6].
Since the first discovery of AAS over 50 years ago, numerous anabolic‐androgenic steroids 
with a variety of functional groups have been produced and/or published. Only a small num‐
ber of them, the so‐called ‘known’ exogenous steroids, have made it to the pharmaceutical mar‐
ket and are still available on the market today. They contain synthetic structures that do not 
occur in natural steroids (e.g. stanozolol and trenbolone, Figure 4). Confirmation of exog‐
enous steroid abuse is relatively straightforward as qualitative demonstration of the compound 
in the sample suffices.
Figure 4. Chemical structures of exogenous steroids: (A) trenbolone (also known as Revalor, Parabolan, Hexabolan, 
Finaplix, trienolone, trienbolone or Tren), and (B) stanozolol (Winstrol, Winny). Stanozolol and trenbolone both contain 
a synthetic, conjugated system.
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Designer steroids are similar to exogenous steroids, containing synthetic structures that are 
thought not to occur naturally, but they have not yet been classified as controlled substances 
and in many cases, like a pro‐hormone, require a chemical reaction or enzymatic alteration 
once in the body to become active [19]. In most cases, they possess additional minor modifica‐
tions compared to the well‐known marketed exogenous steroids. These minor changes render 
their detection with targeted mass spectrometry more difficult, due to the lack of standards. An 
additional worrying feature is that no data are available on the efficacy and safety of the use 
of these compounds [19].
Endogenous steroids, such as testosterone, are steroids that are known to exist naturally, in one 
or more animal species (see also Tables 1 and 2) [20]. Confirmation of endogenous steroids 
abuse is difficult, as simple qualitative or quantitative detection of the compound does not 
suffice. In horses, only testosterone and 17β‐boldenone are generally regarded as endogenous 
(respectively in all horses and in stallions only) (Section 3.1). The classification of a steroid as 
‘endogenous’ is, however, a grey area. The ‘semi’‐endogenous presence of 17β‐boldenone and 
related compounds, for example, in mares and geldings, is a complicating factor in doping 
control. Proper investigation on the origin of these AASs is required to continue to ensure 
adequate doping policies in the future [20, 21] (Section 4).
3.1. Reference ranges for AAS in humans and horses
Over the years, multiple studies have measured excreted concentrations of testosterone in 
humans, both in blood plasma and in urine (Table 1). On average‐levels of testosterone are 
up to 10 times as great in adult males as in adult females [22]. The reference ranges for blood 
test of adult males are between 1.8 and 7.5 ng/mL (>50 years old) and 2.90 and 13 ng/mL (<50 
years old), while the reference range for adult females is between 0.2 and 0.85 ng/mL [23, 24]. 
As the metabolic consumption of testosterone in males is greater too, the daily production 
was estimated to be about 20 times higher in men [25].
Futterweit et al. were one of the first to set a reference range for testosterone in urine, using 
thin layer chromatography (TLC) and gas chromatography (GC) [26]. Doberne and New and 
Tresguerres et al. on the other hand used a, at that time, very new and high‐tech isotopi‐
cally labelled ligand binding assay (Radioimmunoassay, RIA) [27, 28]. Mass spectrometric 
(MS) methods, coupled to either gas chromatography (GC) or liquid chromatography (LC), 
were introduced later on in the 1980s and 1990s and used for all types of anti‐doping screen‐
ing and quantitative methods [29–32]. Pesant et al. were an exception, using a competitive 
immunochemiluminescent assay for the determination of testosterone concentrations [23]. 
The detailed evolution of analytical methods used for steroid detection will be discussed in 
detail later on in this chapter (Section 5.1).
Generally, less data are available regarding the normal ranges of excretion of testosterone 
and its related metabolites in horses. Testosterone and its precursors/metabolites are known to 
be endogenous in males (stallions and geldings) and female horses at varying concentrations 
[20]. In a recent study, high performance liquid chromatography/mass spectrometry (HPLC‐
MS) was used to investigate the effect of γ‐oryzanol supplementation on endogenous testos‐
terone levels in horses. During that study, urine β‐testosterone concentrations were always 
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lower than 1.7 ng/mL for mares and geldings, Mösseler [33]. Both Ho et al. and Popot et al. 
measured β‐Bol, ADD as well as testosterone in urine (and faeces) of (male) horses [34, 35]. Ho 
et al. used an immunoaffinity column (IAC) purification, followed by liquid chromatography/
mass spectrometry (LC‐MS/MS) analysis on a quadrupole‐time of flight (Q‐ToF) instrument 
while Popot’s extraction protocol included diethylether extraction, lipid removal, HPLC puri‐
fication, derivatization and GC‐EI/MS/MS detection. Testosterone levels measured by Popot 
et al. were between 71 and 214 ng/mL (stallions). If urine samples are being analysed with gas 
chromatography/mass spectrometry (GC‐MS) for the identification of cryptorchidism (pres‐
ence of an undescended testis in geldings), a cut‐off level of 8 ng/mL is held as a marker. 
Testosterone levels below 8 ng/mL are regarded normal for geldings and, according to these 
thresholds, no β‐Bol should be found in geldings [36]. Bonnaire et al. found that plasma con‐
centrations for cycling mares vary between 20 and 60 pg/mL and can go up to 245–350 pg/mL 
in bearing mares. Urine concentrations in cycling mares were found to be between 1.4 and 
20.1 ng/mL (GC‐MS) [37].
Reference Population Female
n Mean (ng/mL) Outliers (ng/mL)
Futterweit et al. [26] American 10 4.0* 5.3*
Doberne et al. [27] American 10 2.8* n.a.
Tresguerres et al. [28] American 16 16* n.a.
Van Renterghem et al. [30] Caucasian 1004 12 200
Martinez‐Brito et al. [31] Latin‐American 1181 13 54
*Recalculated based upon an expected average daily urine excretion of 1.5 L/day.
n.a. data non available.
Table 2. Reference ranges for total testosterone in urine of humans (female).
Reference Population Male
n Mean (ng/mL) Outliers (ng/mL)
Futterweit et al. [26] American 10 114* 167*
Doberne et al. [27] American 10 56* n.a.
Tresguerres et al. [28] American 26 100* 231*
Gonzalo‐Lumbreras et al. [29] Spanish 12 125** 191**
Van Renterghem et al. [30] Caucasian 2027 37 >100
Martinez‐Brito et al. [31] Latin‐American 2454 60 >200
Moon et al. [32] Korean 337 26 >150
*Recalculated based upon an expected average daily urine excretion of 1.5 L/day.
**Samples were collected early in the morning, at the maximum of the excretion curves.
n.a. data non available.
Table 1. Reference ranges for total testosterone in urine of humans (male).
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β‐Boldenone levels measured by Popot et al. (GC‐EI/MS/MS) in stallions varied between 1.0 
and 2.9 ng/mL urine (n = 7) [35]. The range of free and conjugated (e.g. boldenone sulphate) 
determined by Ho et al. (LC‐MS/MS, Q‐ToF) was between 0.1 and 4.34 ng/mL (n = 63, from 37 
male horses), and the mean was 1.27 ± 1.03 ng/mL [34]. Boldenone was not detected in geld‐
ings (n = 8), in line with the results of Leung et al. (GC‐MS) [36]. The mean β‐boldenone con‐
centration measured in male horses by Dehennin et al. (GC‐MS) was 0.34 ng/mL (minimum 
0.02, maximum 1.51 ng/mL) (n = 156) [38].
3.2. Threshold levels for endogenous steroids
Additionally, as sport horses are frequently subjected to doping analysis, normal levels can 
be derived from anti‐doping regulatory bodies accepted levels. Very strict zero‐tolerance poli‐
cies are held for most steroids, but exceptions have been made for the naturally occurring 
androgenic steroids: boldenone and testosterone (and stanozolol and nandrolone, according 
to a limited number of regulatory organs) (Table 3).
Pu et al. were able to directly detect boldenone sulphate and glucuronide conjugates in 
horse urine by ion trap liquid chromatography‐mass spectrometry [39] and Ho et al. [34] 
and Popot et al. [35] also found endogenous β‐boldenone in urine and faeces of entire males. 
Following these results, IFHA (Article 6, 2017), RMTC (Banned Medication List, 2017) and 
FEI (2017 Equine Prohibited Substances List) abandoned the zero‐tolerance policy for entire 
male horses; a threshold for free and conjugated boldenone of 15 ng/mL was set. Despite this 
threshold for stallions, the presence of β‐Bol in urine from mares or geldings is still prohibited. 
Nevertheless, occasionally traces of β‐Bol or related metabolites have been found in urine of 
horses that were not treated with AAS [40].
For testosterone, thresholds were set for mares and fillies (unless in foal), up to 55 ng/mL 
free and conjugated testosterone in urine and 20 ng/mL urine for geldings are allowed. For 
entire male horses, amounts in excess of amounts existing naturally in the untreated horse at normal 
physiological concentrations are considered to be non‐naturally occurring physiological con‐
centrations. The international threshold for testosterone in plasma is 100 pg/mL for geldings. 
Currently, no threshold for mares is set yet, but it is being suggested to introduce the same 
threshold of 100 pg/mL (IFHA and FEI, 2017).
For nandrolone or nortestosterone (free and conjugated), the RMTC threshold was set at 1 ng/
mL in urine (geldings, fillies and mares). In male horses other than geldings, 45 ng/mL of 
metabolite, 5σ‐estrane‐3β,17σ‐diol in urine or a ratio in urine of 5σ‐estrane‐3β,17σ‐diol to 
5σ‐estrene‐3β,17σ‐diol of > 1:1 is considered to be indicative for abuse. Only a limited num‐
ber of regulatory organs (e.g. The Canadian Horse Racing Board, CHRB) set a threshold for 
stanozolol, at 1 ng/mL urine. For FEI and IFHA, for example, stanozolol is listed as a banned 
substance and therefore strictly forbidden. Estranediol has also been added to the list of thresh‐
old substances. Free and conjugated (5α‐estrane‐3β,17α‐diol), at 45 ng/mL in urine of male 
horses (other than geldings).
All these thresholds and reference ranges are within the low ppm or ppb range, in matrices 
such as urine, blood and faeces, underlining the need for very sensitive and specific detection 
methods that are able to determine the exact steroidal status of (race) horses in‐ and out‐of‐
competition. This explains the extensive use of sensitive, state‐of‐the‐art mass spectrometric 
methods in this field.
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4. Analytical instrumentation
4.1. Historical evolution
Both in food residue and sport drug surveillance laboratories, big progress has been made over 
the last few decades regarding the detection of residues and forbidden substances (doping, 
incl. AAS) in different matrices [18, 41] (Figure 5).
In the 1960s and early 1970s, thin layer chromatography (TLC) combined with fluorescence 
detection (TLC‐FL) was the most used technique. Later on in the 1970s, immunoassays such 
as enzyme linked immunosorbent assays (ELISA) and enzyme immunoassay (EIA) were 
developed and widely used. Both EIA and ELISA systems [42] are based on the principle of 
immunoassay linked to an enzyme rather than radioactivity as the reporter label (radioim‐
munoassay, RIA) [27, 28].
Mass spectrometry (MS) was introduced in the late 1970s but took until the late 1990s to con‐
quer analytical labs worldwide. MS was first coupled to gas and later on to liquid chromatog‐
raphy (GC‐MS and LC‐MS) [43, 44]. Modern MS instruments are able to perform MS in series. 
The detection is carried out in the same compartment (MSn) or in different compartments 
(MS/MS), on both the precursor ion and fragment ions, allowing to reach higher specificity 
and sensitivity. Over the years, various methods have been designed as screening tools to 
detect a large number of compounds in different drug classes, including anabolic steroids.
4.2. GC‐MS versus LC‐MS
GC‐MS has been the gold standard for the detection of residues and anabolic steroids (in urine) 
for many years. In the past decades, however, there has been a general shift from GC‐MS 
towards LC‐MS/MS for drug residue and in doping control testing [45, 46]. This is mainly 
attributed to the rapid improvement of LC‐MS(/MS) in recent years, leading to better sensitivity, 
faster instrument turnaround time and the ability to handle heat labile and large biomolecules.
Recent work has proven that ultra‐high performance liquid chromatography‐MS (UHPLC‐
MS/MS) instrumentation can provide exceptional detection capability of AAS in multiple 
equine matrices including mane hair [21], plasma [47] and urine [40, 48]. The development 
of ultra‐high performance liquid chromatography (UHPLC), using sub‐2 μm particles in the 
column, allowed higher flow rates and improved separation of compounds with similar or 
identical masses and retention times (e.g. α‐ and β‐isomers of testosterone), while at the same 
time shortening the run time. LC‐MS/MS is widely used by anti‐doping testing laboratories for 
this purpose, and several rapid methods have been described to simultaneously detect differ‐
ent classes of compounds [20, 49, 50].
High resolution mass spectrometry (HRMS), on the other hand, operating at higher resolutions 
of 7500 up to more than 140,000 full width at half maximum (FWHM), is being optimized 
not as a screening technique only, but also for specific ‘omics’ biomarker approaches such as 
metabolomics, proteomics and transcriptomics [51–55].
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Recently, however, this shift to LC has come to a standstill, with even a partial shift back to 
GC, depending on the type of analysis [45, 46, 56, 57]. As of 2010, GC is again gaining impor‐
tance as an anti‐doping approach, but then coupled to MS/MS, complimentary to LC‐MS/
MS. GC‐MS(/MS) is an important tool for analysing saturated steroid metabolites, as they 
suffer from poor ionization [58]. Alternatively, many urinary screening procedures include 
hydrolysis of phase‐II metabolites, releasing the free compounds for detection, allowing to 
determine the overall concentration of the compound (free and conjugated), as used to define 
the thresholds of both the IFHA and FEI (See earlier, Figure 5). Additionally, comprehensive 
two‐dimensional separation techniques LC × LC or GC × GC are also being developed [59, 60].
Therefore, at the moment, LC and GC techniques can be considered complimentary, as both 
techniques have their specific advantages and disadvantages, depending on the compound, 
matrix and goal of the analysis.
4.3. Gas chromatography–combustion‐isotope ratio MS (GC‐C‐IRMS)
As mentioned earlier, the administration of synthetic steroids, especially tackling the exog‐
enous administration of steroids of endogenous origin (e.g. testosterone), is an important obsta‐
cle for anti‐doping regulatory organs. Therefore, doping control laboratories accredited by 
the WADA require methods of analysis that allow endogenous steroids to be distinguished 
from their synthetic analogues in urine. To that extend, GC is used in hyphenation with 
combustion isotope ratio mass spectrometry (GC‐C‐IRMS) a highly specialized instrumental 
confirmatory technique, measuring the carbon isotope ratio (∆13C) of urinary steroids and con‐
firming their synthetic origin based on the abnormal 13C content [18, 61].
Figure 5. Evolution of analytical techniques used for steroid detection.
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The average isotope ratio of each element (e.g. 12C/13C, 1H/2H) was fixed around the time of the 
earth’s formation. However, variations can occur based on selective enrichment or depletion 
of the heavier isotopes (such as 13C), a process known as fractionation. Fractionation can, for 
example, take place during phase transition; a process also known as equilibrium fraction‐
ation. When water vapour condenses, the lighter isotopes (16O and 1H) tend to remain in the 
vapour phase, while the heavier isotopes (18O and 2H) accumulate in the liquid phase [62]. 
GC‐C‐IRMS is capable of measuring these differences in relative ratio of light stable isotopes 
of carbon (13C/12C), hydrogen (2H/1H), nitrogen (15N/14N) or oxygen (18O/16O) in individual 
compounds, separated from often complex mixtures of components [63, 64].
Already in 1998, Mason et al. showed that when the isotopic composition of 5β‐androstane‐3α,17α‐
diol (the main metabolite of testosterone in bile) was normalized with respect to that of an endog‐
enous reference compound (ERC, cholesterol) in the same sample, the metabolite could be used 
to distinguish between animals treated intramuscularly with testosterone and untreated ani‐
mals [65]. Throughout the last decade, a variety of different methods have been developed and 
the number of different steroids under investigation by IRMS has grown considerably. Misuse 
of norandrosterone, boldenone, corticosteroids or epitestosterone can now be detected with the aid of 
carbon isotope ratios as well [66]. However, some limitations of GC‐C‐IRMS need to be kept in 
mind (Section 4.4.4).
4.4. Matrix and method of choice
The type of matrix used for steroid detection varies according to the specific goal of the analy‐
sis. Traditionally, urine and blood samples are being sampled for the detection of forbidden 
substances in the light of anti‐doping controls, but faeces and hair are possible matrices as 
well [21, 35]. The analysis of equine mane hair, for example, has the potential to greatly extend 
the time period over which the detection of anabolic steroid abuse can be monitored. Parent 
steroids (e.g. testosterone esters) are incorporated into the mane hair and can be detectable for 
months post‐treatment. Additionally, the use of segmental analysis can potentially provide 
additional information on the timing of administration [21]. In residue analysis, meat samples 
and skin swabs are also used [20, 41, 67].
4.4.1. Direct detection and the use of thresholds or zero‐tolerance policy
Depending on the context and the specific class of steroids (endogenous, exogenous or syn‐
thetic, Section 3), the method and matrix of choice can be different. Most methods are based 
upon the direct mass spectrometric detection of the steroid of interest and/or its metabolites 
in biological matrices, merely urine and/or blood samples. This direct detection is coupled to 
two different approaches: a threshold concentration and zero‐tolerance policy.
For most anabolic steroids in horses (Table 3), zero‐tolerance is held: neither the compound 
itself nor its direct metabolites should be detected to consider the sample as clean. For some 
(endogenous) steroids, a threshold concentration has been determined. For boldenone, for 
example, a threshold concentration has been set for stallions (15 ng/mL), while zero‐tolerance 
is held for mares and geldings. For testosterone, a threshold concentration of 20 ng/mL for 
Mass Spectrometry for the Detection of Endogenous Steroids and Steroid Abuse in (Race) Horses and Human Athletes
http://dx.doi.org/10.5772/intechopen.68593
241
geldings and 55 ng/mL for mares is held. For stallions, no threshold has been set as the natu‐
ral testosterone concentration is under the influence of age, seasonal variations and whether 
or not the stallion is a breeding stallion [68]. The idea of a threshold concentration relies on 
the statistical likelihood that a certain concentration can be detected in an untreated horse. The 
threshold must be based upon populations’ studies and relevant to the concentrations mea‐
sured post‐treatment [49]. If the threshold concentration is set too high, concentrations mea‐
sured post‐treatment could be inadvertently listed as endogenous. If the threshold is set too 
low, non‐treated horses could be unjustly banned from competitions and their owners/train‐
ers sanctioned.
4.4.2. Measuring biological effect
As an alternative to the direct measurement of steroids, a range of assays have been devel‐
oped measuring the biological effect of the steroids rather than the responsible compounds them‐
selves. Two categories of assays can be distinguished: biosensors and biomarkers.
Biosensors utilize biological techniques to detect steroidal activity in a sample ex vivo, 
whereas biomarker techniques aim to monitor perturbation of ‘normal’ in vivo physiological 
parameters. With the rise of high resolution non‐targeted approaches, the latter use of specific 
qualitative biomarkers has gained popularity over the last few years. Biomarkers or biological 
markers are metabolites that are measurable indicators of some biological state or condition, 
e.g. (illegal) treatment with a certain compound or compound cocktail. Biomarker monitor‐
ing can already be considered a new era in human anti‐doping [69] and different biomarker 
approaches are being developed for equine purposes at the moment. As such, longitudinal 
monitoring of biomarkers can reveal non‐physiological responses independently of the used 
doping technique or substance and may cause sanctioning of illicit practices [70].
An example hereof is an efficient strategy that has been developed to screen for abuse of nan‐
drolone, a ‘semi’‐endogenous steroid in stallions (Table 3), monitoring the endogenous ste‐
roid profile disruption in urine and blood upon nandrolone administration [70]. A panel of 
(endogenous) steroids of interest was extracted from equine urine and plasma samples and 
quantified by GC‐MS/MS. Statistical processing of the collected data permitted to establish 
statistical models capable of discriminating control samples from those collected post‐admin‐
istration. These statistical models succeeded in predicting the compliance status of routine 
samples collected from racing horses.
4.4.3. Phase I and II metabolites
A typical problem associated with the direct detection of boldenone and other (related) AAS 
is that they often do not result in a measurable excretion of the parent steroid in urine and 
faeces. Instead, these AAS are metabolized, by the liver, and excreted as their more hydrophilic 
phase I and II metabolites [39]. Phase I metabolites are merely formed through classical oxida‐
tive and reductive reactions. Phase‐II metabolites arise from the conjugation of these hydroxyl 
groups as either sulphates or ß‐glucuronides. These conjugates account for up to 90% of the 
excreted metabolites, making them an important class for screening [71].
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In the case of boldenone metabolism, the 1,4‐diene‐3‐one structure of the A‐ring appears to 
stabilize the steroid for reductive metabolism and boldenone‐17ß‐sulphate is the major (phase 
II) metabolite [72]. Therefore, extraction of urine and faeces samples includes hydrolysis of both 
metabolites, releasing the free compounds for detection. Hydrolysing conjugates allow deter‐
mining the overall concentration (free and conjugated) of the compound, as used to define 
the thresholds of both the IFHA and FEI (Section 3.2). Ho et al., for example, identified intact 
boldenone sulphoconjugates as a direct evidence for the endogenous nature of boldenone in 
entire male horses.
These conjugates can, however, also be used as biomarker in equine anti‐doping. They have 
been used is the detection of boldenone misuse. Exogenous boldenone is known to be exten‐
sively conjugated in phase‐II metabolism. Gomez et al. found that after boldenone treatment, 
boldenone sulphate and in some cases α‐Bol sulphate were present in urine samples, together 
with low concentrations of exogenous boldenone (the original, active drug) and BM1 (the 
main boldenone metabolite, 5β‐androst‐1‐en‐17β‐ol‐3‐one) [73]. Thus, according to Gomez 
et al., BM1, β‐Bol and α‐Bol sulphates may be used as markers for the exogenous administra‐
tion of boldenone, and they can be used to reduce the number of samples to be analysed by 
GC‐IRMS. In samples where boldenone and BM1 are detected at low concentrations and these 
concentrations thus might be of endogenous origin, further analysis by GC‐IRMS will only 
be needed if boldenone sulphates and α‐Bol sulphates are also present. GC‐IRMS will then be 
used to confirm exogenous administration.
4.4.4. Limitations of GC‐C‐IRMS
As described earlier, GC‐C‐IRMS can be used as a confirmatory tool. However, the limitations 
of the IRMS approach need to be kept in mind. In equine, anti‐doping establishing IRMS as a 
confirmatory tool is not that straightforward, as one of the factors influencing fractionation is 
genetic. Monocotyledonous plants (C4 plants), such as corn and desert or marine plants, typi‐
cally have ∆13C values varying from −8 to −20%. Most dicotyledons (C3 plants, including up to 
95% of the plants on earth) have ∆13C values varying from −22 to −35%. Because animals can 
only incorporate carbon through the ingestion of plant (or animal matter), the carbon isotope 
ratios in an animal will reflect the isotope ratios of the food source: ‘you are what you eat’ [63]. 
For horses, this implies that ∆13C values are very close to the ones of exogenous substances, 
hampering the ability to differentiate between endogenous and exogenously administered 
compounds (steroids).
Another problem associated with the use of IRMS in horses is the ‘third sex’: geldings. If tests 
are performed to determine if an atypical steroid profile in humans is due to administration of 
an endogenous steroid androsterone (Andro), etiocholanolone (Etio) and/or the androstane‐
diols (5α‐ and 5β‐androstane‐3α,17β‐diol) are typically analysed by IRMS to determine the 
∆13C values. The ratios of these target compounds are compared to the ∆13C ratio of an endog‐
enous reference compound (ERC) such as 5β‐pregnane‐3α,20α‐diol (Pdiol) [74]. For geldings, 
it is very difficult to obtain such a reliable endogenous reference compound (ERC). It is possible to 
find a reliable ERC for stallions and mares, but this ERC is not consistent with geldings (per‐
sonal communication, Laboratoire des Courses Hippiques, L.C.H.). In this context, Piper et 
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al. and Cawley and Flenker also described some of the complexities that can be encountered 
to obtain valid ∆13C measurements from GC‐C‐IRMS and the need for careful interpretation of 
all relevant information concerning an individual’s metabolism in order to make an informed 
decision with respect to a doping violation [66, 75].
Overall, this illustrates that the direct detection approach (relying on threshold concentra‐
tions), the biosensor/biomarker approaches and GC‐C‐IRMS have their limitations, including 
for requiring large population studies for validation and the fact that statistical outliers can 
be present at any time. These limitations are a part of the reason that zero‐tolerance is still the 
preferred method to deal with ‘semi’‐endogenous steroids, unless irrefutable evidence has 
been gathered proving the endogenous prevalence of a certain compound, in mares, geldings 
and/or stallions.
5. (Equine) biological passport
To conquer the latter limitations, WADA introduced the athlete biological passport (ABP) for 
human athletes in 2009. An APB is an individual, electronic record for professional athletes in which 
profiles of biological markers of doping and results of doping tests are collated over a period of time. The 
ABP is considered to be an effective tool in the fight against doping as monitoring selected 
biological variables over time can indirectly reveal the effects of doping, rather than attempt‐
ing to detect the doping substance or method itself (Section 4.4.2) [76].
The concept of launching a similar equine biological passport (EBP) is not new, the earlier dis‐
cussions started back in 2010, but the tone and urgency of these discussion among veterinary 
and regulatory authorities are changing in the wake of recent doping scandals (e.g. cobalt 
scandal in Australia, 2015). This sudden public focus might spur funding that helps turn com‐
plicated concepts, such as introduction of EBPs as a means to curtail doping, into reality.
With the metabolomics technology invested in the equine passport, the industry can be proactive 
in identifying those who are engaging in doping practices, without necessarily knowing what 
the specific substance is, eliminating the strict reliance on targeted analysis of post‐ racing 
urine and blood samples. Every horse has a unique metabolic signature that can be identified by 
monitoring metabolites or markers. This individualized approach facilitates a better under‐
standing of the specific traits of each horse, providing more precise measurement of the bio‐
logical effect of training, stress and/or drugs (controlled medication or doping) than is available 
with current technologies. Metabolomics is already recognized as a cutting‐edge science in 
human medicine and anti‐doping.
Additionally, the EBP can include monitoring the genes of racehorses, identifying changes 
throughout their careers, to combat gene doping. Gene doping is defined by the World Anti‐
Doping Agency (WADA) as ‘the non‐therapeutic use of cells, genes, genetic elements or of the modu‐
lation of gene expression, having the capacity to improve athletic performance’. Suspected targets for 
gene doping are erythropoietin (EPO), myostatin and the insulin‐like growth factor (ILGF).
Unfortunately, the use of biological passports will be a logistic and analytical challenge to all 
but the top‐flight racing analytical labs around the world. The EBP is a whole‐of‐ organization 
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 initiative requiring high‐tech equipment and the co‐operation of analysts (scientists), stew‐
ards, anti‐doping investigators and veterinarians to ensure all of the available information 
concerning prohibited practices to be integrated in real time. Racing New South Wales 
(Racings N.S.W., Australia) and leading French racing authorities (including L.C.H.) are cur‐
rently working together on the development of EBPs.
In the past, doping sinners have always been a step or two ahead of the authorities, but with 
these new spectrometric techniques changing the way of handling drug abuse—not by find‐
ing the drugs but finding changes in the physiology of the horse created by the drugs—the 
gap may be about to close. A cheerful outlook for the fight against doping abuse.
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